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Background: For patients with liver cirrhosis awaiting liver transplantation who suffer from refractory ascites
(RA), standard treatment consists of repeated large volume paracentesis. The automated low-flow ascites-
pump (alfapump) offers an innovative treatment alternative for patients with RA, if TIPSS is contraindicated
or ineffective. This study addresses the feasibility of alfapump treatment in patients awaiting liver
transplantation.
Methods: Between 2012 and 2018, patients listed for liver transplantation who were treated with an alfa-
pump were included in this retrospective single centre study.
Results: Of 22 patients listed for liver transplantation and treated with an alfapump, 14 were finally trans-
planted. Alcohol-related liver disease was the most common aetiology for liver cirrhosis (n = 11), followed by
hepatitis C, hepatitis B and NASH. Mean age at listing was 56.3 years and 68.2% of patients were male. The
average daily ascites volume pumped by the device was 1076 ml. During transplant surgery, no alfapump-
related complications occurred. The alfapump was removed at the end of the transplant procedure in eight
patients and left in place in three patients for up to 104 days, whereas three patients had the pump removed
prior to the transplantation. Overall survival was significantly better in patients that were finally trans-
planted (log-rank p < 0.0001). Five patients (22.7%) required at least one alfapump-related re-intervention.
Conclusion: Treatment with an alfapump in patients on the liver transplant waiting list with refractory ascites
is feasible. The alfapump did not affect the transplant procedure and was explanted in most patients at the
end of the transplant surgery.
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PRBC Packed red blood cells
RA Refractory ascites
TIPSS Transjugular intrahepatic portosystemic shuntIntroduction
Patients with liver cirrhosis and portal hypertension frequently
develop ascites during the evolution of the disease as a consequence
of systemic inflammation, splanchnic vasodilation, low systemic vas-
cular resistance and reduced effective arterial blood volume leading
to an increased reabsorption of sodium and water [1,2]. In the initial
phase, ascites is controlled with optimized fluid and salt manage-
ment and diuretic treatment with an aldosterone antagonist in com-
bination with a loop diuretic [3,4]. Refractory ascites (RA) is defined
as ascites that cannot be mobilised by medical therapy or that reoc-
curs early after large volume paracentesis (LVP). Survival in patients
with RA is as low as 50% at one year [5,6].
Standard treatment of RA consists of repeated large-volume para-
centesis in combination with albumin substitution [6,7]. However,
LVP offers only temporary relief of ascites-associated symptoms.
Fig. 1. Overview of patient selection.
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with a decreased quality of life and considerable costs [8,9]. Alterna-
tively, RA can be treated with a transjugular intrahepatic portosyste-
mic shunt (TIPSS) that reduces portal pressure and therefore the
main driver for the development of ascites [7,10]. Several studies and
meta-analyses have shown that TIPSS is effective in reducing the
need for paracentesis and improves survival compared to LVP and
albumin replacement therapy [11-13]. However, TIPSS has a number
of relative contraindications that are associated with an unfavourable
outcome including pre-existing hepatic encephalopathy, or reduced
cardiac function [14-16].
In patients with a contraindication for TIPSS, the alfapump offers
an alternative treatment option for RA. Efficacy regarding removal of
ascites and a decrease in paracentesis frequency have been demon-
strated in the Pioneer study [17] in 2013. In 2017, standard of care
treatment (LVP) was compared with alfapump therapy in a random-
ized controlled trial. This trial confirmed the efficacy of treatment
with the alfapump compared to standard of care treatment at a com-
parable risk [18]. These results have been recently confirmed in a
meta-analysis summarizing the available evidence to date [19]. Fur-
thermore, treatment with the alfapump was associated with an
improved nutritional status [18] and quality of life [8] compared to
standard of care with LVP.
Liver transplantation is the only curative treatment option in most
patients with liver cirrhosis and RA. Depending on the availability of
donor organs, waiting time on the list may exceed one year. There-
fore, finding the ideal bridging treatment for patients with RA on a
liver transplant waiting list is of great importance.
The aim of this study was to evaluate safety and feasibility of
treatment with the alfapump and to describe first experiences
regarding the intra- and perioperative aspects of liver transplantation
in patients with this device in situ.
Material and methods
This study is a retrospective analysis of data collected from
patients listed for liver transplantation in a tertiary care university
transplant centre who were treated with an alfapump for RA
between 2012 and 2018. Within this timeframe, all patients treated
with an alfapump while being on the waiting list for liver transplan-
tation were included, whereas patients with an alfapump that were
not on the waiting list for liver transplantation were excluded. Fol-
low-up visits took place as standard of care for patients with the alfa-
pump and/or patients listed for liver transplantation every one to
three months according to the clinical need. For this analysis, patients
were followed up until the last visit prior to July 2020 or death. The
decision regarding the insertion of a TIPSS or an alfapump was taken
by an interdisciplinary team consisting of hepatologists and trans-
plant surgeons.
Primary outcome of this analysis was feasibility of liver transplan-
tation in patients with an alfapump in situ. Secondary endpoints
were survival of patients with an alfapump listed for liver transplan-
tation, efficacy of alfapump measured as total und daily volume
pumped, cause of death in patients with and without LT, evolution of
liver-disease prior to transplantation based on Child-Pugh stage,
MELD and MELD-Na score and technical complications.
The study has been approved be the Ethics Committee of the Can-
ton Bern, Switzerland (KEK 073−2012).
Statistics
Continuous data are reported as mean and standard deviation
(SD) and median and range in case of normal distribution or other-
wise as median and range and compared by unpaired t-test and Wil-
coxon-Mann-Whitney test. Categorical data are presented as
percentages. Kaplan Meier Survival curves and Log-rank test were2
used to display and compare survival of patients with and without
liver transplantation.
Statistical analyses were performed using IBM SPSS Version 25.0
(Chicago, Illinois, USA) and GraphPad Prism version 8 for Windows,
GraphPad Software, La Jolla, California, USA.Results
From 12/2012 to 07/2018, 45 patients in total have been treated
with an alfapump in our centre. Of these, 22 have been listed for liver
transplantation (LT) before or while being treated with the alfapump
and consequently included in this analysis (Fig. 1). The decision to
implant an alfapump was taken jointly by the hepatologist and the
transplant surgeon.
Disposition at listing for LT
At listing for LT, mean patient age was 56.3 § 8.8 years and 68.2%
of patients were male. Transplanted patients were younger
(53.6 § 8.7 years) at listing than those that deceased prior to LT
(61.0 § 7.2 years). Alcoholic liver disease was the most frequent aeti-
ology of liver cirrhosis (11/22; 50%), followed by hepatitis C (4/22;
18.2%) and hepatitis B (3/22; 13.6%) (Table 1). Four patients suffered
from a HCC within Milan criteria. Of these, three patients had an
underlying alcohol-related cirrhosis and one a hepatitis C-related cir-
rhosis. Scores and laboratory parameters at listing for LT and at alfa-
pump implantation are specified in Table 1 and Table 2, respectively.Disposition at LT
Of the initially 22 patients listed for LT and concomitantly treated
with an alfapump, 14 were finally transplanted (50% female),
whereas eight male patients died prior to LT, seven while being on
the transplant list and one after having been delisted seven weeks
prior to death due to progressive liver disease. The average duration
on the waiting list for transplanted patients was 289 § 152 days and
for those that were not transplanted 191 § 192 days. Mean age at LT
was 54.3 § 8.4 years. At transplantation, 11 patients had the alfa-
pump still in situ, whereas three patients had the pump explanted
prior to LT.
The amount of ascites pumped in patients that were finally trans-
planted was 214.5 § 217.9 L on average, resulting in a mean daily
volume of 1121 § 421 ml. Transplanted patients had the alfapump
for a mean duration of 177 § 131 days. Scores and laboratory param-
eters at LT are specified in Table 2.
Table 1
Baseline study population.
w/o LT n = 8 with LT n = 14 all patients n = 22
Male/female n (%) 8/0 (100/0) 7/7 (50/50) 15/7 (68.2/31.8)
Age at listing for LT (years)
mean/SD 61.0 § 7.2 53.6 § 8.7 56.3 § 8.8
median (range) 61.0 (52−72) 55.0 (39−70) 56.5 (39−72)
Age at alfapump implantation (years)
mean/SD 61.1 § 7.5 53.9 § 8.5 56.5 § 8.7
median (range) 61.0 (53−73) 55.5 (40−71) 56.5 (40−73)
Underlying chronic liver disease
- Alcohol 6 (2 HCC) 5 (1 HCC) 11 (3 HCC)
- Hepatitis B 3 3
- Hepatitis C 1** 3 (1 HCC) 4 (1 HCC)
- NASH 1 1 2
- Wilson‘s disease 1 1
- Turner-associated cholostasis 1 1
Child-Pughscore* mean, SD 9.4 § 1.4 8.9 § 0.9 9.0 § 1.1
median, range 9.0 (8−12) 9.0 (8−11) 9.0 (8−12)
stage A (n) 0 0 0
B (n) 6 12 18
C (n) 2 2 4
MELD score* mean, SD 15.8 § 3.6 14.7 § 6.5 15.1 § 5.5
median, range 15.5 (11−23) 12.5 (7−29) 14.5 (7−29)
MELD-Na score* mean, SD 19.9 § 5.3 18.5 § 5.7 19.0 § 5.4
median, range 21 (13−26) 17 (11−29) 18.5 (11−29)
Albumin (g/L)* mean, SD 30.3 § 9.0 26.9 § 6.7 28.1 § 7.6
median, range 28 (15−45) 26.5 (18−41) 27 (15−45)
Bilirubin (mmol/L)* mean, SD 46.4 § 20.5 43.1 § 32.3 44.3 § 28.1
median, range 40.5 (15−76) 34 (11−110) 39 (11−110)
Creatinine (mmol/L)* mean, SD 195.6 § 210.6 129.2 § 72.1 153.4 § 138.1
median, range 109.5 (67−695) 113.5 (58−331) 109.5 (58−695)
INR* mean, SD 1.41 § 0.24 1.28 § 0.20 1.33 § 0.22
median, range 1.38 (1.1−1.8) 1.26 (1.0−1.6) 1.26 (1.0−1.8)
* at listing for LT.
** cured hepatitis C an autoinflammatory syndrome.
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Mean LT duration was 251 § 49 min. Intra-operative requirement
for packed red blood cells, fresh frozen plasma and thrombocyte units
was 9.5 § 6, 16 § 9 and 4 § 2.7, respectively. The alfapump was
removed in eight patients at the end of the LT, and kept in place in
three patients for another 15, 93 and 104 days post LT. One patient
experienced postoperative bleeding not related to the alfapump. Two
patients required temporary postoperative renal replacement ther-
apy.
Survival
Mortality after LT was 28.6% (n = 4) during the observation period,
whereas the 90 day mortality after alfapump implantation was 7.1%.
Reasons for death were primary non-function of the graft (2 days
post LT), intracerebral bleeding (3 days post LT, the donor liver was
re-transplanted in another recipient), pulmonary metastases of a
HCC (one year post LT) and septic shock (3 years post LT, after re-
transplantation) (Table 3). In all four patients, mortality was not
related to the alfapump. As expected, survival in transplanted
patients was significantly better than in patients not transplanted
(Fig. 2). In patients not transplanted, mortality was 100% with a
90 day mortality after implantation of the alfapump of 25%. Death
occurred mostly in the context of infection and/or progressive liver
disease (Table 3). Overall 90 day mortality after alfapump implanta-
tion was 13.6% in this series.
Complications before LT
Of the patients who were finally transplanted, the alfapump had
to be removed in three patients prior to LT. One patient had an intra-
abdominal and one a systemic infection, the latter in combination3
with a pump dysfunction. In a third patient with advanced malnutri-
tion, a pump pocket skin lesion in combination with a dysfunctional
peritoneal catheter led to the explantation of the pump (Table 4).
Of the 8 patients who died while on the waiting-list, one patient
had a pump pocket empyema that was clearly linked to the alfapump
system, whereas three patients suffered from an abdominal infection
with an uncertain link to the pump system. Three patients died from
progressive liver disease, one of them with an infection of unclear
focus, and one patient presented with a small bowel perforation not
directly related to the pump catheter system.
Laboratory follow-up
Of the patients going on to transplantation, 11 were Child-Pugh
stage B and three stage C at the time of alfapump implantation
(Table 2), whereas 10 were Child-Pugh stage B and four stage C at LT.
Mean MELD was 15.1§ 2.8 and 18.4§ 7.4, respectively. While having
the alfapump in situ, creatinine increased from 113.6 § 35.7 to
157.7 § 91.4 mmol/L, bilirubin from 40.7 § 30.3 to 63.9 § 82.9 mmol/
L and the INR from 1.31 § 0.25 to 1.42 § 0.41 in patients that were
finally transplanted. Albumin levels remained in the same range
(27.7 § 2.7 vs. 28.5 § 5.8 g/L) within the same period of time,
although albumin was not administered in the context of continuous
ascites drainage by the alfapump. Zinc levels were considerably low
at alfapump implantation (7.1 § 1.8 nmol/L, normal level >12 nmol/
l).
Discussion
For patients with refractory or difficult to treat ascites, therapeutic
options are limited. Large volume paracentesis is a well established
procedure and associated with a low risk for complications [20,21].
However, the repetitive accumulation of significant amounts of
Table 2
Summary at alfapump implantation and LT.
at AP impl. at AP impl. at AP impl. at LT
all patients n = 22 w/o LT n = 8 with LT n = 14 p° n = 14 p'
Male/female n (%) 15/7 (68.2/31.8) 8/0 (100/0) 7/7 (50/50) 7/7 (50/50)
Age (years)
- mean, SD 56.5 § 8.7 61.0 § 7.5 53.9 § 8.3 0.060 54.3 § 8.4
- median (range) 56.5 (40−73) 61.0 (53−73) 55.5 (40−71) 56.0 (41−71)
Child-Pugh Score
- mean, SD 9.1 § 0.4 8.9 § 0.4 9.2 § 0.4 0.071 9.4 § 0.6 0.435
- median (range) 9.0 (8−10) 9.0 (8−9) 9.0 (9−10) 9.0 (9−11)
Stage A 0 0 0 0
Stage B 19 8 11 10
Stage C 3 0 3 4
MELD score
- mean, SD 16.0 § 5.3 16.4 § 6.4 15.1 § 2.8 0.515 18.4 § 7.4 0.297
- median (range) 15.0 (8−25) 15.0 (12−21) 16.0 (8−25) 18.0 (10−32)
MELD-Na score
- mean, SD 17.3 § 4.5 17.0 § 3.6 17.5 § 5.0 0.808 22.3 § 6.7 0.026*
- median (range) 17.5 (11−25) 17.0 (12−22) 18.0 (11−25) 22.0 (13−35)
Albumin (g/L)
- mean, SD 27.1 § 3.7 26.1 § 5.1 27.7 § 2.7 0.433 28.5 § 5.8 0.626
- median (range) 27.0 (20−33) 26.5 (20−33) 27.5 (23−33) 30.0 (16−37)
Bilirubin (mmol/L)
- mean, SD 36.8 § 26.4 29.9 § 17.5 40.7 § 30.3 0.367 63.9 § 82.9 0.268
- median (range) 24.0 (10−115) 23.5 (11−66) 31.5 (10−115) 26.0 (8−286)
Creatinine (mmol/L)
- mean, SD 119.6 § 38.8 130.1 § 44.3 113.6 § 35.7 0.349 157.7 § 91.4 0.097
- median (range) 116.0 (41−195) 123.0 (74−195) 115 (41−182) 123.5 (89−421)
INR
- mean, SD 1.30 § 0.21 1.28 § 0.14 1.31 § 0.25 0.758 1.42 § 0.41 0.297
- median (range) 1.30 (1.00−1.80) 1.33 (1.11−1.44) 1.27 (1.00−1.80) 1.35 (1.09−2.66)
Zinc (nmol/L)
- mean, SD 6.9 § 1.9 6.5 § 2.3 7.1 § 1.8 0.547 n.d.
- median (range) 6.6 (4.7−11.3) 5.9 (4.7−11.3) 6.8 (5.0−10.2)
Selenium (nmol/L)
- mean, SD 0.71 § 0.17 0.71 § 0.21 0.70 § 0.15 0.876 n.d.
- median (range) 0.7 (0.4−1.0) 0.7 (0.5−1.0) 0.7 (0.4−0.9)
Vitamin D (25OH) (nmol/L)
- mean, SD 31.9 § 18.4 33.6 § 26.2 30.8 § 11.9 0.771 n.d.
- median (range) 27 (12−86) 29 (12−86) 26 (17−50)
BMI+ (kg/m2)
- mean, SD 24.5 § 5.4 25.9 § 6.0 23.7 § 5.1 0.384 23.0 § 3.5 0.389
- median (range) 23.9 (16.9−36.0) 25.3 (16.9−35.0) 22.5 (17.1−36.0) 23.3 (17.8−31.6)
Hand grip (kg)
- mean, SD 23.1 § 7.8 27.1 § 6.8 20.3 § 7.5 0.074 n.d.
- median (range) 24.9 (10.3−34.1) 27.9 (13.8−34.1) 17.7 (10.3−31.7)
+Dry body weight.
* Significant increase at LT.
p° comparison of patients with and without LT at baseline.
p' comparison of patients with LT at implant alfapump and at LT.
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uptake and quality of life in general [8,22-25].
Alternatively, patients can be treated with a TIPSS, what is associ-
ated with a significant reduction of ascites and an improved survival
[10-12]. However, reduction of ascites usually takes weeks to several
months and shunting of the liver via the TIPSS is associated with a
relevant risk for hepatic encephalopathy (HE) [14].
The alfapump represents an alternative treatment in patients with
RA in whom TIPSS is contraindicated or not feasible. With an alfa-
pump in place, full control of ascites is possible right after the implan-
tation of the pump, what is an advantage if ascites control is required
for months rather than for years. However, in case of a very short
waiting time (less than three months), paracentesis might be the best
option with regard to invasiveness and costs.
After implantation of an alfapump, no regular albumin substitu-
tion is recommended in contrast to the recommendations in the con-
text of large volume paracentesis. In this study, albumin was
administered only in the context of recommended indications such
as hepatorenal syndrome - acute kidney injury (HRS-AKI) and spon-
taneous bacterial peritonitis (SBP). In this series, albumin levels
remained at the same level after AP implantation until4
transplantation without regular substitution of albumin and despite
continuous ascites drainage leading to a considerable loss of albumin
and proteins.
From alfapump implantation to LT an increase in mean MELD,
MELD-Na, bilirubin and creatinine was observed. This is compatible
with a progression of the underlying liver disease while being on the
waiting list for LT. In patients with a three months post transplant fol-
low-up, mean creatinine was only slightly lower compared to LT
(152.1 § 55.6mmol/L vs, 168.5 § 101.1).
Pump outcome in patients with LT
In this series, 14 patients were finally transplanted. In 3 patients
alfapump was removed before LT; one patient suffered from a skin
ulceration of the pump pocket in combination with a pump dysfunc-
tion, one patient had a systemic infection of unclear origin in combi-
nation with a pump dysfunction and a third patient suffered from a
bacterial peritonitis with Klebsiella pneumoniae.
The alfapump was removed in 8 patients at the end of LT and left
in place in 3 patients. Reasons for leaving the alfapump in place after
LT were severe coagulopathy or hemodynamic instability at the end
Table 3
Cause of death pre- and post-transplant.
Pre-LT Post-LT
Deceased n (%) 8 (100) 4 (28.6)
Male n (%) 8 (100) 3 (75)
Reason of death
- Progressive liver disease 2
- Progressive liver disease and infection of unclear focus 1
- Progressive liver disease and peritonitis (Enterococcus faecium and candida) 1
- Abdominal wall phlegmon with communication into abdominal cavity, death due to multi-organ failure, pump not explanted 1
- Septic shock with probable abdominal focus and explantation of the alfapump; patients died 2 days later due to multi-organ failure 1
- Pump pocket empyema and bacterial peritonitis with consecutive explantation of the alfapump; patient died three weeks later due to multi-
organ failure
1
- Small bowel perforation with peritonitis, pump removed during bowel surgery, exitus 4 days later 1
- Primary graft non-function, exitus letalis on day of transplantation 1
- Intracerebral bleeding 3 days after transplantation 1
- Metastatic hepatocellular carcinoma in the lung one year after transplantation 1
- Sepsis with MOF after re-transplantation, 3 years after initial LT with explantation of the alfapump 1
Fig. 2. Survival in patients treated with alfapump.Patients with an implanted AP (n = 22) listed for LT (intention to treat). The LogRank test compares survival of patients finally
transplanted with patients that were not transplanted.
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vated post LT to drain ascites.
Liver transplantation
Based on the patients we analysed in this series, there is no evi-
dence that therapy with the alfapump is an obstacle to liver trans-
plantation. As described in Table 3, 8 patients with alfapump out of
22 died on the waiting list for liver transplantation. This high mortal-
ity was mostly the consequence of the polymorbidity and fragility of
these patients and not primarily related to the alfapump. The position
of the alfapump, in the wall of the right upper abdominal quadrant,
did not interfere with the surgical transplant procedure.
Mortality before and after LT
Within the observation period of this study, seven patients died
while being on the waiting list and one after being delisted due to
progressive liver disease. In two of these patients, death was attrib-
uted to progressive liver disease, whereas in another two patients
progressive liver disease in combination with an infection of
unknown origin and a peritonitis (Enterococcus faecium and candida)
were the most likely cause of death. Three patients died following
abdominal wall phlegmon, pump pocket empyema and septic shock
with probable intraabdominal focus, respectively, and one patient
following small bowl perforation unrelated to the alfapump system
with consecutive complications of peritonitis (Table 3). Whereas in
the patient with the pump pocket empyema a link between the infec-
tion and the alfapump was clearly given, a causative involvement of5
the alfapump could neither be confirmed nor excluded in the other
patients with septic complications, since infections and especially
bacterial peritonitis are frequently observed complications in
patients with advance decompensated liver cirrhosis. The alfapump
was not a reason for an a priori exclusion from LT in any of the
patients of this series. However, in case of serious infection, sepsis or
multi-organ failure with or without relation to the alfapump, patients
might have been temporarily or permanently precluded from LT.
Of 14 patients who received a liver transplant, one died due to pri-
mary graft non-function after intraoperative hyperkalemia, cardiac
instability and cardiopulmonary resuscitation, and one due to an
intracerebral bleed on postoperative day 3 after an initially good evo-
lution post-transplant with extubation on postoperative day 2. Nei-
ther of these two patients had signs for an infection or sepsis with or
without relation to the alfapump. One patient died after re-transplan-
tation as a consequence of sepsis with multi-organ failure three years
after the initial LT and alfapump explantation, and one because of a
HCC-related metastatic lung disease one year after LT and pump
removal. Reason for death was unrelated to the alfapump in all four
patients.Technical adverse events
Most frequently observed technical adverse event leading to revi-
sional surgery in this as well as in other series was blocking of the
peritoneal catheter [26]. This finally led to a change in the catheter
used in subsequent studies and non-study implantations. Pump
exchange due to technical device problems was required in two




Patient group w/o LT with LT all
Patients per group 8 14 22
Ascites pumped by alfapump until LT or end of observation, total amount (L)
- mean, SD 169.0 § 147.8 214.5 § 217.9 198.0 § 192.8
- median (range) 144.3 (36.7−496.0) 125.6 (11.3−653.2) 144.3 (11.3−653.2)
Ascites pumped by alfapump until LT or end of observation, per day (ml)
- mean, SD 996 § 253 1121 § 421 1076 § 367
- median (range) 931 (703−1357) 990 (452−2093) 961 (452−2093)
Pump in situ, days
- mean, SD 160 § 114 177 § 131 171 § 122
- median (range) 117 (40−389) 141 (24−476) 128 (24−476)
Technical adverse events
Peritoneal catheter revision* 0 4 4
Bladder catheter revision 1 0 1
Pump exchange 1 1 2
Smart charger exchange 0 1 1
* 4 events in 2 patients.
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trol group with repeated large volume paracentesis as standard of
care treatment and the retrospective analysis of the data. Further-
more, patients with alcoholic liver cirrhosis are overrepresented in
this series.
Conclusions
The alfapump expands the therapeutic options for RA in patients
waiting for LT. However, TIPSS should be considered in all patients
with RA as treatment option prior to the implantation of an alfapump
since TIPSS is associated with an improved survival and the alfapump
is approved for patients with exclusion criteria for TIPSS only. Careful
patient selection is mandatory, taking into account the expected time
on the liver transplant waiting list. On average, the alfapump was in
situ for 6 months and the mean volume of ascites transported was
approximately one litre per day. Pump-related re-interventions were
most frequently required due to peritoneal catheter problems. The
alfapump did not interfere with the transplant procedure and no sur-
gical complications related to the alfapump could be identified in this
series. The alfapump was removed at the end of the liver transplanta-
tion in most patients but kept in place in a few patients for a limited
period of time. Pre-transplant mortality was associated with progres-
sive liver disease, while post-transplant mortality was independent
of the alfapump. The work presented here shows that ascites man-
agement with an alfapump in patients on the waiting list for LT is a
feasible treatment option in carefully selected candidates. Further-
more, LT was not negatively affected by the alfapump in situ in this
series. Surgical revisions were mainly related to catheter-associated
technical problems. Technical improvements and optimization of
management will further reduce the need for revisions in future
patients.
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